LEXARIA BIOSCIENCE CORP. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
LEXARIA BIOSCIENCE CORP. (LEXX) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$69.83 thousand for the 12-month period ending 2024-08-31, per its 10-K filed 2024-11-26.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2024-11-26
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-08-31 was $9.50K.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-05-31 was -$41.39K, a 2330.23% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-02-29 was $15.27K.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-11-30 was -$53.22K.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was -$69.83K.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$221.69K.
- LEXARIA BIOSCIENCE CORP. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$764.61K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-08-31 | $9.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$31.89K derived: sum of 2 quarters · filed 2024-11-26 | -$16.62K derived: sum of 3 quarters · filed 2024-11-26 | -$69.83K 10-K · filed 2024-11-26 |
| 2024-05-31 | -$41.39K 10-Q · filed 2024-07-12 | -$26.12K derived: sum of 2 quarters · filed 2024-07-12 | -$79.33K 10-Q · filed 2024-07-12 | -$223.25K derived: sum of 4 quarters · filed 2024-11-26 |
| 2024-02-29 | $15.27K 10-Q · filed 2024-04-09 | -$37.94K 10-Q · filed 2024-04-09 | -$181.86K derived: sum of 3 quarters · filed 2024-11-26 | -$180.00K derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-11-30 | -$53.22K 10-Q · filed 2024-01-12 | -$197.13K derived: sum of 2 quarters · filed 2024-11-26 | -$195.28K derived: sum of 3 quarters · filed 2024-11-26 | -$197.28K derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-08-31 | -$143.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$142.06K derived: sum of 2 quarters · filed 2024-11-26 | -$144.06K derived: sum of 3 quarters · filed 2024-11-26 | -$221.69K 10-K · filed 2024-11-26 |
| 2023-05-31 | $1.86K 10-Q · filed 2024-07-12 | -$147.00 derived: sum of 2 quarters · filed 2024-07-12 | -$77.78K 10-Q · filed 2024-07-12 | |
| 2023-02-28 | -$2.00K 10-Q · filed 2024-04-09 | -$79.63K 10-Q · filed 2024-04-09 | ||
| 2022-11-30 | -$77.63K 10-Q · filed 2024-01-12 | |||
| 2022-08-31 | -$764.61K 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |